Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 88

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 1
Chunk 88
---
 in specified circumstances, many of which differ from each other in significant
ways and may not have the same effect, thus complicating compliance efforts.

Insurance
Coverage and Reimbursement

Significant
uncertainty exists as to the insurance coverage and reimbursement status of any products for which we may obtain regulatory approval.
In the United States, sales of any product candidates for which regulatory approval for commercial sale is obtained will depend in part
on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities
and health programs in the United States such as Medicare and Medicaid, managed care providers, private health insurers and other organizations.
These third-party payors are increasingly reducing reimbursements for medical products and services. The process for determining whether
a payor will provide coverage for a drug product may be separate from the process for setting the reimbursement rate that the payor will
pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might
not include all of FDA-approved drugs for a particular indication. A payor’s decision to provide coverage for a drug product does
not imply that an adequate reimbursement rate will be approved. Further, coverage and reimbursement for drug products can differ significantly
from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us
to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and
adequate reimbursement will be applied consistently or obtained in the first instance.

 21 

Human
Capital Resources

As
of December 31, 2024, the Company had 9 full-time employees, including its Chief Executive Officer, Vininder Singh, and 8 part-time employees,
advisors, and consultants, including its Chief Financial Officer, Josh Blacher. None of these employees are covered by a collective bargaining
agreement, and we believe our relationship with our employees is good. We also engage consultants on an as-needed basis to supplement
existing staff.

We
believe that our future success will depend, in part, on our continued ability to attract, hire and retain qualified personnel. In particular,
we depend on the skills, experience and performance of our senior management and R&D personnel. We compete for qualified personnel
with other healthcare technology, pharmaceutical, and healthcare companies, as well as universities and non-profit research institutions.
We provide competitive compensation and benefits programs to